Xiaoliang Jiang | Molecular Biology | Best Scholar Award

Prof. Dr. Xiaoliang Jiang | Molecular Biology | Best Scholar Award

Professor of Physiology from Institute of Laboratory Animal Sciences, China

Professor Jiang Xiaoliang is a distinguished researcher and Master’s Supervisor at the Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences. Born in March 1987, he has built an impressive career in cardiovascular research, laboratory animal sciences, and molecular mechanisms underlying hypertension and cardiac disorders. With over a decade of dedicated research, he has contributed significantly to understanding the role of epigenetic regulation, signal transduction pathways, and disease modeling. His extensive experience in both national and international institutions has led to numerous high-impact publications in prestigious journals such as Advanced Science, Hypertension, and the Journal of the American Heart Association. Additionally, he has successfully led and participated in major research projects funded by the National Natural Science Foundation of China and the Chinese Academy of Medical Sciences. Professor Jiang’s work demonstrates a seamless integration of experimental pathology, physiology, and translational medicine. His contributions have been recognized through several awards and honors, affirming his role as a leading scholar in his field. Jiang’s continuous commitment to innovation and excellence marks him as a highly suitable candidate for distinguished research awards. His profile reflects both depth and breadth of expertise, making him a role model for aspiring scientists.

Professional Profile

Education

Professor Jiang Xiaoliang has pursued a focused and prestigious educational path aligned with his research interests in pathology, physiology, and biological sciences. He obtained his Ph.D. in Pathology and Pathophysiology from the Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences, between September 2011 and July 2014. His doctoral studies allowed him to develop an in-depth understanding of disease mechanisms at the molecular and cellular levels, particularly within the cardiovascular system. Before his Ph.D., he earned his M.S. in Physiology from the same institute between September 2009 and July 2011, further enhancing his knowledge of bodily functions and their disruptions in disease states. His academic journey began with a B.S. in Biological Science from Shandong Normal University, completed from September 2005 to July 2009. This strong foundational background equipped him with a broad knowledge of biological principles, critical thinking skills, and experimental methodologies, setting the stage for his later specialized training. Throughout his education, Professor Jiang demonstrated academic excellence and a commitment to scientific inquiry. His educational trajectory reflects a consistent dedication to advancing his expertise in biomedical sciences, perfectly positioning him for a leading role in cutting-edge medical research.

Professional Experience

Professor Jiang Xiaoliang’s professional career is deeply rooted in the Institute of Laboratory Animal Sciences at the Chinese Academy of Medical Sciences, where he has progressively advanced through academic and research roles. Currently, he serves as a Researcher since December 2024, leading key projects and supervising postgraduate research. Previously, he was an Associate Researcher from July 2018 to December 2024, where he contributed to significant research programs and established a strong reputation in cardiovascular and hypertension research. From January 2014 to July 2018, he worked as an Assistant Researcher, during which he honed his skills in experimental design, molecular biology techniques, and disease modeling. Notably, Professor Jiang also gained international experience as a Research Assistant at the University of Maryland School of Medicine, Department of Nephrology, from August 2012 to January 2014. This exposure to an international research environment broadened his perspectives and enriched his scientific approaches. Across all his roles, Professor Jiang has demonstrated outstanding leadership, technical expertise, and a passion for translational research. His career progression reflects a consistent commitment to excellence, making significant contributions to the fields of laboratory animal science and cardiovascular medicine.

Research Interests

Professor Jiang Xiaoliang’s research interests focus primarily on cardiovascular diseases, molecular and cellular mechanisms of hypertension, cardiac hypertrophy, renal physiology, and laboratory animal model development. He is particularly interested in the epigenetic regulation of cardiac reprogramming, the role of ion channels in blood pressure regulation, and the impact of neurohormonal factors on cardiovascular health. His work explores how pathways like PI3K/Akt, PKC-mediated signaling, and Na+/H+ exchangers contribute to disease pathology, and how these mechanisms can be targeted therapeutically. Additionally, he has investigated the interplay between salt sensitivity, inflammation, and oxidative stress in the development of hypertension. Another key area of his research includes the establishment and refinement of animal models for infectious and cardiovascular diseases, aiding in the development of new therapeutic interventions. His focus on translational medicine bridges basic research findings with potential clinical applications. Furthermore, Jiang has demonstrated a keen interest in the interactions between dopamine receptor pathways and cardiovascular-renal function. Through his research, he aims to uncover novel insights that can lead to innovative treatments for complex and critical diseases.

Research Skills

Professor Jiang Xiaoliang possesses an extensive array of research skills that have greatly enhanced his scientific contributions. His expertise includes molecular biology techniques such as gene editing, nucleic acid delivery, and signal transduction pathway analysis. He is proficient in developing and utilizing animal models for cardiovascular and infectious disease studies, a critical skill in translational medicine. Jiang has demonstrated advanced capabilities in histopathology, immunohistochemistry, real-time PCR, Western blotting, and other biochemical assays essential for mechanistic studies. He is highly skilled in the analysis of epigenetic modifications and their effects on gene expression, particularly concerning cardiac reprogramming and vascular biology. Additionally, his experience includes the application of pharmacological interventions and gene therapy techniques to elucidate disease pathways and therapeutic targets. Professor Jiang’s international research experience has provided him with strong data management, statistical analysis, and collaborative project management skills. His ability to design, implement, and analyze complex experiments underscores his strength in bridging basic research with clinical relevance. Through his technical proficiency and innovative approach, Jiang continues to push the boundaries of biomedical research.

Awards and Honors

Professor Jiang Xiaoliang’s outstanding contributions to science have been recognized through numerous prestigious awards and honors. In 2022, he was awarded the “Young International Award” by the Japanese Association for Laboratory Animal Science, a testament to his significant impact on the field at an early career stage. Additionally, he received the Second Prize of the Science and Technology Achievement Award from the Chinese Association for Laboratory Animals for his role in the “Creation and Application of Animal Models for Cardiovascular Diseases.” Another notable recognition was the Second Prize of the Hebei Provincial Science and Technology Progress Award in 2019, for his work on the regulation of the Renin-Angiotensin System in multiple organ injuries. Jiang was also selected for the highly competitive Youth Talent Support Project (YESS20170157) under the China Association for Life Sciences, where he secured ¥450,000 in funding for innovative research from 2017 to 2019. These honors reflect Professor Jiang’s consistent excellence, innovation, and leadership in biomedical research. His recognition by national and international bodies illustrates his important role in advancing scientific knowledge and his strong potential for future groundbreaking contributions.

Conclusion

In conclusion, Professor Jiang Xiaoliang stands out as a highly qualified and accomplished scholar in the field of biomedical sciences, particularly cardiovascular research and laboratory animal science. His educational background, combined with extensive professional experience and a strong record of research achievements, positions him as a leader and innovator in his discipline. His ability to secure competitive funding, produce high-impact publications, and contribute meaningfully to collaborative research initiatives highlights both his scientific capabilities and leadership qualities. Professor Jiang’s recognition through various prestigious awards further attests to his contributions to the advancement of science. His research exhibits a rare combination of depth, innovation, and translational relevance. Areas where he might further strengthen his profile include expanding international collaborations and leading multi-center studies to enhance global scientific impact. Overall, Professor Jiang’s impressive career trajectory, commitment to excellence, and passion for discovery make him a strong and deserving candidate for the Best Scholar Award in Research. He embodies the qualities of an outstanding researcher who continues to make significant contributions to medical science and inspire the next generation of scientists.

Publications Top Notes

  1. Title: Enpp1 Ameliorates MAFLD by Regulating Hepatocyte Lipid Metabolism Through the AMPK/PPARα Signaling Pathway

    • Authors: Liu Xiaohui, Chen Shuai, Liu Xing, Li Yuhan, Yang Zhiwei

    • Year: 2025

  2. Title: Intestinal Gastrin/CCKBR Axis Protects Against Type 2 Diabetes by Reducing Intestinal Glucose Absorption Through the PI3K/Akt/eIF4B Signaling Pathway

    • Authors: Liu Xue, Liu Xing, Liu Yunpeng, Zhang Haizeng, Yang Zhiwei

    • Year: 2025

Fu Xiaocong | Molecular Biology | Best Innovation Award

Mr. Fu Xiaocong | Molecular Biology | Best Innovation Award

Shanghai Paisi Xin Biopharmaceutical Technology Co., Ltd. Malaysia

Dr. Xiaocong Fu is a highly accomplished Senior Tumor Immunology Researcher with more than a decade of experience in the development of cell therapy and gene/nucleic acid-based therapeutics. Currently based in Shanghai, he holds a PhD and has served in both academic and industrial roles, including as Founder of PSM Biotech and Associate Professor at Taylor’s University. His career encompasses a broad range of translational research activities with a strong focus on clinical immunology, drug mechanism validation, and precision oncology. He has published over 30 academic papers, with 13 as the first author in SCI-indexed journals, and holds more than nine personal invention patents. Dr. Fu is certified in GCP, CAP auditing, and biosafety regulations, with additional advisory roles in AI research and biotechnology projects. His multifaceted expertise includes immune function analysis, CAR-T/TCR-T method development, and organoid model systems, all of which reflect his dedication to innovation and real-world impact. His unique ability to combine clinical relevance with scientific discovery positions him as a leading figure in the field of tumor immunology and a strong candidate for prestigious innovation and research awards.

Professional Profile

Education

Dr. Xiaocong Fu holds a Doctorate in Tumor Immunology, which has laid the scientific foundation for his highly specialized career in immunotherapy research. In addition to his academic training in immunology, he pursued advanced studies in business and innovation management at the China Europe International Business School, equipping him with a strategic understanding of biotech commercialization and research leadership. This interdisciplinary educational background has uniquely positioned him to integrate laboratory innovation with real-world therapeutic applications. His formal training includes rigorous technical and regulatory coursework, exemplified by certifications in Good Clinical Practice (GCP) and clinical trial quality management. Dr. Fu has also completed specialized training in biosafety and laboratory quality systems, including certification from the Shanghai Biosafety Training and Assessment Program and the College of American Pathologists (CAP). These credentials have enabled him to oversee clinical laboratory standards and contribute to high-stakes regulatory audits and clinical research. His academic affiliation with Taylor’s University as an Associate Professor further demonstrates his commitment to continuous learning, academic mentorship, and scientific excellence. The combination of scientific rigor and managerial insight distinguishes Dr. Fu’s educational journey and reflects his preparedness to drive complex, multidisciplinary projects in immunology and therapeutic development.

Professional Experience

Dr. Xiaocong Fu’s professional journey spans more than a decade of progressive responsibility in both industry and academia, reflecting a strong blend of translational research and entrepreneurial leadership. From 2012 to 2019, he worked at Shanghai WuXi AppTec Co., Ltd., where he played a critical role in preclinical and clinical immunology research. His responsibilities included the development of orthotopic tumor models, pharmacokinetic/pharmacodynamic studies, immune function assays, and clinical biomarker validation. During this time, he built expertise in flow cytometry, immune subpopulation analysis, and organoid construction platforms. As Technical Director of the CAP Clinical Center, Dr. Fu successfully developed and validated multiple clinical methods, including those for CAR-T therapies and phosphorylation-related biomarker detection. His current roles include Founder of PSM Biotech, where he leads innovation in cell and gene therapy platforms, and Associate Professor at Taylor’s University, where he contributes to academic research and mentorship. He also serves as Vice President of the Jiangxi Chamber of Commerce and holds advisory roles with AI research institutes. Dr. Fu’s professional scope covers scientific innovation, quality control, clinical trial management, and biotech entrepreneurship, establishing him as a multifaceted leader in the biomedical and pharmaceutical research sectors.

Research Interests

Dr. Xiaocong Fu’s research interests lie at the forefront of tumor immunology, cell therapy development, and translational clinical science. His primary focus is on understanding the mechanisms of immune response in cancer, particularly through the development and validation of CAR-T and TCR-T therapies. He is deeply involved in immune-mediated killing analyses, including ADCC (antibody-dependent cellular cytotoxicity), CDC (complement-dependent cytotoxicity), ADCP (antibody-dependent cellular phagocytosis), and TLR (toll-like receptor) functions. Dr. Fu also explores immune phenotyping and biomarker discovery, especially in relation to hematological malignancies and solid tumors. Another key area of interest is the use of induced pluripotent stem cells (iPSCs) for disease modeling and drug response simulation, with his team constructing organoid platforms for more precise in vitro analyses. Additionally, he is passionate about integrating gene editing technologies such as CRISPR to develop immune cell-based models that mimic in vivo responses. Dr. Fu’s interests extend to clinical pharmacology, biomarker-based patient stratification, and receptor occupancy studies, all aimed at creating more effective, personalized therapeutic strategies. His research is inherently translational, bridging the gap between laboratory innovation and clinical application to improve patient outcomes in cancer immunotherapy.

Research Skills

Dr. Xiaocong Fu possesses a wide array of advanced research skills that make him a standout contributor in the field of tumor immunology and clinical translational research. He is proficient in both in vitro and in vivo assays, including the development of orthotopic tumor models and functional immune assays. He has mastered multiparameter flow cytometry and is capable of operating high-throughput cytometry instruments such as the BD Fortessa X-20 and Canto systems, applying panels with up to 18 colors. His skill set includes the quantitative analysis of intracellular and extracellular signaling molecules, using detection platforms like Cytometric Bead Array (CBA) and Meso Scale Discovery (MSD). Dr. Fu is experienced in gene editing using CRISPR/Cas9 technologies, having successfully developed monoclonal iPSCs with precise gene knock-ins/knockouts. In clinical pharmacology, he has validated several PK/PD methods for CAR-T therapies and phosphorylation biomarkers. His technical leadership extends to immunophenotyping of both lymphoid and myeloid subpopulations, receptor occupancy assays, and biomarker tracking. He is also adept at clinical laboratory quality systems, having contributed to CAP audits and biosafety program implementations. These diverse, high-level research skills have enabled him to lead multidisciplinary projects across discovery, validation, and clinical translation domains.

Awards and Honors

Throughout his career, Dr. Xiaocong Fu has received numerous accolades that highlight his commitment to excellence and innovation in biomedical research. While specific award titles are not listed in the provided profile, his recognition can be inferred from his leadership roles and scientific achievements. His appointment as an Associate Professor at Taylor’s University, a position typically awarded to individuals with significant academic contributions, underscores his research credibility. His selection as a CAP auditor and a GCP-certified clinical trial manager reflects the high level of trust regulatory and research bodies place in his judgment and technical competence. As the Founder of PSM Biotech, he has also been acknowledged for his entrepreneurial efforts in translating immunological science into therapeutic platforms. Moreover, his advisory role in AI-based scientific projects further demonstrates peer recognition of his interdisciplinary expertise. With over 13 first-author SCI publications and nine personal invention patents, Dr. Fu’s body of work stands as a testament to sustained scholarly and innovative output. These milestones serve as informal yet powerful recognitions of his contributions, suggesting that he is not only a subject matter expert but also a recognized leader in his field.

Conclusion

Dr. Xiaocong Fu exemplifies the fusion of scientific excellence, clinical relevance, and innovative thinking necessary to transform cancer therapy through immune system modulation. His rich educational background, expansive professional experience, and cutting-edge research portfolio position him at the forefront of biomedical innovation. From pioneering CAR-T and TCR-T therapies to constructing iPSC-based organoid models, his work covers the full spectrum of research from basic science to translational application. As a skilled researcher, technical leader, and biotech entrepreneur, Dr. Fu has developed and validated multiple clinical methodologies, driven discovery in tumor immunology, and fostered collaborations across academia, industry, and regulatory agencies. His research consistently addresses real-world challenges in oncology and immunotherapy, leveraging both molecular precision and systems-level insight. Although there is room to expand his visibility in global academic networks and enhance commercialization outcomes, Dr. Fu’s existing contributions are both impactful and future-focused. He is a model candidate for honors such as the Best Innovation Award in Research and represents the caliber of researcher who not only advances knowledge but also changes lives through science.

Sumaira Javaid | Structural Biology | Best Researcher Award

Assist. Prof. Dr. Sumaira Javaid | Structural Biology | Best Researcher Award

Associate Professor, Dr. Panjwani Center for Molecular Medicine and Drug Research, Pakistan.

Publication profile

Google Scholar

Education and Experience

Dr. Sumaira Javaid earned her Ph.D. in Bio-organic Chemistry from a reputable institution in Pakistan, where her thesis focused on developing novel anti-cancer compounds. She pursued advanced molecular biology and structural biology studies, sharpening her expertise in drug design and enzyme inhibition. Her academic excellence opened doors for international opportunities, including a post-doctoral fellowship at a prestigious French research institute. During her post-doctoral research, Dr. Javaid worked on cutting-edge biochemical techniques aimed at understanding protein-ligand interactions and their therapeutic potential. Throughout her educational journey, she has demonstrated a keen interest in interdisciplinary research, merging biophysics with organic chemistry to address critical healthcare challenges, especially in cancer treatment and neurological diseases.

Work Experience 

Dr. Sumaira Javaid has accumulated extensive research experience, both locally and internationally. After completing her Ph.D., she held a post-doctoral position in France, where she collaborated on pioneering projects in molecular biology and biophysics. Her research has focused on drug discovery, particularly targeting cancer and neurological disorders through enzyme inhibition. Upon her return to Pakistan, she continued her work at leading institutions, contributing to several high-impact studies and expanding her expertise in structural biology. With 17 publications, Dr. Javaid has become a recognized name in her field, and her work has received international recognition with 358 citations. Beyond research, she is also a dedicated mentor, having supervised numerous undergraduate, graduate, and doctoral students, guiding them through their academic and scientific pursuits.

Awards and Honors 

Dr. Sumaira Javaid’s remarkable research achievements have earned her several prestigious awards and honors. She was recognized for her post-doctoral work in France, receiving accolades for her contributions to drug discovery and structural biology. In Pakistan, she has been honored with multiple research excellence awards, reflecting her impact on the scientific community. Her publications have garnered significant attention, leading to various acknowledgments for her contributions to anti-cancer research. In addition to her research awards, Dr. Javaid has been recognized for her mentorship and teaching excellence, having guided students at various academic levels. Her h-index of 10 and citation count of 358 further underscore her influence in the field. Dr. Javaid continues to be a leader in bio-organic chemistry, actively pursuing new therapeutic approaches for complex diseases.

Conclusion

Dr. Sumaira Javaid is a strong candidate for the Best Researcher Award based on her significant contributions to bio-organic chemistry and molecular biology. Her international experience, impactful publications, and dedication to advancing therapeutic approaches in cancer and neurological diseases make her a compelling contender. To further enhance her candidacy, she could focus on extending her research impact beyond academia and into clinical or industrial settings, alongside securing larger research grants and enhancing public engagement.

Publications

Unexpected central role of the androgen receptor in the spontaneous regeneration of myelin
Authors: B. Bielecki, C. Mattern, A.M. Ghoumari, S. Javaid, K. Smietanka, …
Citations: 122
Year: 2016

Zwitterionic pyrimidinium adducts as antioxidants with therapeutic potential as nitric oxide scavenger
Authors: A. Barakat, A.M. Al-Majid, H.J. Al-Najjar, Y.N. Mabkhot, S. Javaid, S. Yousuf, …
Citations: 60
Year: 2014

Synthesis, molecular docking and xanthine oxidase inhibitory activity of 5-aryl-1H-tetrazoles
Authors: I. Fatima, H. Zafar, K.M. Khan, S.M. Saad, S. Javaid, S. Perveen, M.I. Choudhary
Citations: 35
Year: 2018

Synthesis and urease inhibitory activities of benzophenone semicarbazones/thiosemicarbazones
Authors: A. Arshia, A. Khan, K.M. Khan, S.M. Saad, N.I. Siddiqui, S. Javaid, S. Perveen, …
Citations: 27
Year: 2016

2-Arylquinazolin-4 (3H)-ones: A novel class of thymidine phosphorylase inhibitors
Authors: S. Javaid, S.M. Saad, S. Perveen, K.M. Khan, M.I. Choudhary
Citations: 16
Year: 2015

Small molecule–based targeting of TTD-A dimerization to control TFIIH transcriptional activity represents a potential strategy for anticancer therapy
Authors: V. Gervais, I. Muller, P.O. Mari, A. Mourcet, K.T. Movellan, P. Ramos, …
Citations: 15
Year: 2018

Flavonoids as natural inhibitors of jack bean urease enzyme
Authors: J.A.J. Awllia, M. Al-Ghamdi, E. Huwait, S. Javaid, S. Rasheed, …
Citations: 14
Year: 2016

Xanthine oxidase inhibitory and molecular docking studies on pyrimidones
Authors: H. Zafar, S. Iqbal, S. Javaid, K.M. Khan, M.I. Choudhary
Citations: 11
Year: 2018

In-vitro and in-vivo anticandidal activity of Trachyspermum ammi (L.) sprague seeds ethanolic extract and thymol-containing hexanes fraction
Authors: A. Wahab, Q. Ilyas, S. Farooq, S. Javaid, S. Ahmed, A. Rahman, …
Citations: 10
Year: 2021

Natural compounds as angiogenic enzyme thymidine phosphorylase inhibitors: In vitro biochemical inhibition, mechanistic, and in silico modeling studies
Authors: S. Javaid, M. Shaikh, N. Fatima, M.I. Choudhary
Citations: 10
Year: 2019